Page last updated: 2024-11-07

2,3,4,6-tetra-o-acetyl-beta-d-glucopyranosyl isothiocyanate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,3,4,6-tetra-O-acetylglucopyranosylisothiocyanate: RN given refers to (beta-D)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID99462
SCHEMBL ID1357029
MeSH IDM0124136

Synonyms (27)

Synonym
14152-97-7
2,3,4,6-tetra-o-acetyl-.beta.-d-glucopyranosyl isothiocyanate
[(2r,3r,4s,5r,6r)-3,4,5-triacetoxy-6-isothiocyanato-tetrahydropyran-2-yl]methyl acetate
gitc
2,3,4,6-tetra-o-acetyl-beta-d-glucopyranosyl isothiocyanate, for chiral derivatization, >=98.0% (hplc)
2,3,4,6-tetra-o-acetyl-beta-d-glucopyranosyl isothiocyanate
tagit
beta-d-glucopyranosyl isothiocyanate, 2,3,4,6-tetraacetate
nsc 224452
2,3,4,6-tetra-o-acetylglucopyranosylisothiocyanate
AKOS015898494
SCHEMBL1357029
WOWNQYXIQWQJRJ-UXXRCYHCSA-N
W-200114
(2r,3r,4s,5r,6r)-2-(acetoxymethyl)-6-isothiocyanatotetrahydro-2h-pyran-3,4,5-triyl triacetate
2,3,4,6-tetra-o-acetyl-b-d-glucopyranosyl isothiocyanate
mfcd00043085
2,3,4,6-tetra-o-acetyl-?-d-glucopyranosyl isothiocyanate
T70264
2,3,4,6-tetra-o-acetyl-beta-d-glucopyranosyl isothiocyanate [for hplc labeling]
2,3,4,6-tetra-o-acetyl-b-d-glucopyranosylisothiocyanate
DTXSID90931112
b-d-glucopyranosyl isothiocyanate,2,3,4,6-tetraacetate
2,3,4,6-tetra-o-acetyl-beta-d- glucopyranosyl isothiocyanate
2,3,4,6-tetra-o-acetyl- beta -d-glucopyranosyl isothiocyanate
2,3,4,6-tetra-o-acetyl--d-glucopyranosylisothiocyanate
(2r,3r,4s,5r,6r)-2-(acetoxymethyl)-6-isothiocyanatotetrahydro-2h-pyran-3,4,5-triyltriacetate

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The proposed method was found to be suitable and accurate for the quantitative determination of TJ0711 enantiomers in rat plasma, and it can be used in pharmacokinetic studies."( Stereoselective HPLC assay of TJ0711 enantiomers by precolumn derivatization with GITC using UV detection and its application in pharmacokinetics in rats.
Fan, Z; Li, G; Qiu, J; Si, L; Sun, S, 2009
)
0.35
" The validated assay was successfully applied to the quantification of the (R)- and (S)-enantiomers of both carvedilol and its pharmacologically active 4'-hydroxyphenyl metabolite in human plasma in support of a human pharmacokinetic study."( A validated enantioselective LC-MS/MS assay for the simultaneous determination of carvedilol and its pharmacologically active 4'-hydroxyphenyl metabolite in human plasma: application to a clinical pharmacokinetic study.
Furlong, MT; He, B; Mariannino, T; Mylott, W; Shen, J; Stouffer, B; Zhao, S, 2012
)
0.38
" A pilot pharmacokinetic study of this new β-adrenolytic compound has shown that (-)-(S)-TWo8 is eliminated faster than its antipode."( Enantioselective LC/ESI-MS/MS analysis and pharmacokinetic and tissue distribution study of (2RS)-1-(7-methoxy-1H-indol-4-yloxy)-3-(2-(2-methoxyphenoxy)ethylamino)-propan-2-ol in rats.
Groszek, G; Szymura-Oleksia, J; Walczak, M, 2012
)
0.38

Bioavailability

ExcerptReferenceRelevance
" administration, the absolute bioavailability (31."( Stereoselective disposition of carvedilol in man after intravenous and oral administration of the racemic compound.
Akpan, W; Kaufmann, B; Neugebauer, G; Reiff, K, 1990
)
0.28

Dosage Studied

ExcerptRelevanceReference
" Specificity of the method for 1045U85 was demonstrated using spiked plasma samples as well as plasma samples from dosed animals."( Development and validation of a chiral LC method for analysis of the four stereoisomers of 1045U85 in plasma.
Deal, DL; McNulty, MJ; Page, TL, 1994
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (28)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (14.29)18.7374
1990's9 (32.14)18.2507
2000's7 (25.00)29.6817
2010's8 (28.57)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.43

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.43 (24.57)
Research Supply Index3.47 (2.92)
Research Growth Index4.90 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.43)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (6.90%)5.53%
Reviews1 (3.45%)6.00%
Case Studies1 (3.45%)4.05%
Observational0 (0.00%)0.25%
Other25 (86.21%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]